Back to News
Market Impact: 0.35
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
Source: Nasdaq
Healthcare & BiotechCorporate Guidance & OutlookCompany Fundamentals
The article centers on a Phase 3 clinical-trial failure that created divergent outcomes among biotechnology companies. Alnylam Pharmaceuticals outlined plans to advance zilebesiran, its investigational RNA interference therapy intended to provide sustained blood-pressure control. The available text does not specify the failed drug, trial metrics, or the magnitude of the related share-price moves.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.05
Ticker Sentiment
ALNY-0.15
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- Leonardo raises 2026 order guidance after strong 9-mth performance
- HelloFresh Q3 core profit tops forecasts as marketing cuts hit orders
- Microsoft declines Nscale Texas expansion ahead of $35 bln IPO - report